Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pd-1 Inhibitors”

Showing 20 of 0 results

Not applicableStudy completedNCT05535998
What this trial is testing

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT

Who this might be right for
Hepatocellular Carcinoma
Yunfei Yuan 743
Early research (Phase 1)Looking for participantsNCT07231445
What this trial is testing

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 100
Early research (Phase 1)Looking for participantsNCT06963814
What this trial is testing

Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Cancer
HC Biopharma Inc. 252
Testing effectiveness (Phase 2)UnknownNCT05035381
What this trial is testing

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

Who this might be right for
MSI-H Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07469956
What this trial is testing

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Who this might be right for
Pancreatic Cancer Resectable
Sun Yat-sen University 30
Testing effectiveness (Phase 2)WithdrawnNCT05582031
What this trial is testing

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Who this might be right for
Anal Squamous Cell CarcinomaColorectal NeoplasmsSoft Tissue Sarcoma+5 more
Translational Research in Oncology
Large-scale testing (Phase 3)Looking for participantsNCT06086457
What this trial is testing

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Who this might be right for
Esophageal Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 436
Early research (Phase 1)UnknownNCT03743298
What this trial is testing

Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Aivita Biomedical, Inc. 20
Not applicableNot Yet RecruitingNCT07350824
What this trial is testing

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

Who this might be right for
HCCMinimal Residual DiseaseRecurrence
Tongji Hospital 276
Testing effectiveness (Phase 2)UnknownNCT04860674
What this trial is testing

A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma

Who this might be right for
Gray Zone LymphomaRelapse/RecurrenceChemotherapy Effect
Zhejiang Cancer Hospital 20
Not applicableStudy completedNCT03387540
What this trial is testing

Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions

Who this might be right for
MyocarditisCardiac Complication
Groupe Hospitalier Pitie-Salpetriere 104
Testing effectiveness (Phase 2)UnknownNCT05341193
What this trial is testing

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma
Sun Yat-sen University 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03869034
What this trial is testing

HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Sun Yat-sen University 40
Testing effectiveness (Phase 2)Looking for participantsNCT07178340
What this trial is testing

Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach

Who this might be right for
Hepatoid Adenocarcinoma of Stomach
Peking University Cancer Hospital & Institute 30
Testing effectiveness (Phase 2)UnknownNCT04099589
What this trial is testing

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

Who this might be right for
Upper Tract Urinary CarcinomaMuscle-invasive Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 64
Not applicableLooking for participantsNCT06926140
What this trial is testing

Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer

Who this might be right for
Lung Cancers
Guang'anmen Hospital of China Academy of Chinese Medical Sciences 240
Testing effectiveness (Phase 2)Study completedNCT02579811
What this trial is testing

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

Who this might be right for
Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center 40
Early research (Phase 1)Study completedNCT02636036
What this trial is testing

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

Who this might be right for
Colorectal CancerSquamous Cell Carcinoma of the Head and NeckEpithelial Tumor
Akamis Bio 51
Testing effectiveness (Phase 2)WithdrawnNCT05290194
What this trial is testing

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Who this might be right for
RadiotherapyPD-1 InhibitorCapecitabine+1 more
Fifth Affiliated Hospital, Sun Yat-Sen University
Not applicableStudy completedNCT06253364
What this trial is testing

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Who this might be right for
HCCRecurrence
Chen Xiaoping 462
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation